UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma

Acta neuropathologica, 2018-11, Vol.136 (5), p.793-803

2018

Volltextzugriff (PDF)

Case report: EGFR fusion mutation combined with EGFR amplification responds to EGFR-TKI therapy

Frontiers in oncology, 2024-03, Vol.14, p.1347282

2024

Volltextzugriff (PDF)

Detecting EGFR gene amplification using a fluorescence in situ hybridization platform based on digital microfluidics

Talanta (Oxford), 2024-03, Vol.269, p.125444-125444, Article 125444

2024

Volltextzugriff (PDF)

EGFR/CEP7 high polysomy is separate and distinct from EGFR amplification in glioblastoma as determined by fluorescence in situ hybridization

Journal of neuropathology and experimental neurology, 2024-04, Vol.83 (5), p.338-344

2024

Volltextzugriff (PDF)

TP53 Mutation and Extraneural Metastasis of Glioblastoma: Insights From an Institutional Experience and Comprehensive Literature Review

The American journal of surgical pathology, 2021-11, Vol.45 (11), p.1516-1526

2021

Volltextzugriff (PDF)

IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroups

Neuro-oncology (Charlottesville, Va.), 2022-05, Vol.24 (5), p.809-820

2022

Volltextzugriff (PDF)

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial

Neuro-oncology (Charlottesville, Va.), 2019-01, Vol.21 (1), p.106-114

2019

Volltextzugriff (PDF)

Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis

Lung cancer (Amsterdam, Netherlands), 2022-02, Vol.164, p.52-55

2022

Volltextzugriff (PDF)

Immunohistochemical and molecular genetic study on epithelioid glioblastoma: Series of seven cases with review of literature

Pathology, research and practice, 2018-05, Vol.214 (5), p.679-685

2018

Volltextzugriff (PDF)

The antitumor activity of osimertinib plus palbociclib in non-small cell lung cancer patient-derived xenograft (PDX)/2D/3D culture models harboring EGFR amplification and CDKN2A/2B homozygous deletions

Neoplasia (New York, N.Y.), 2024-11, Vol.57, p.101039, Article 101039

2024

Volltextzugriff (PDF)

Heterogeneity of resistant mechanisms in an EGFR-TKI relapsed patient with EGFR amplification and response to nimotuzumab: A case report

Frontiers in oncology, 2022-08, Vol.12

2022

Volltextzugriff (PDF)

Genetic Alterations of Epidermal Growth Factor Receptor in Glioblastoma: The Usefulness of Immunohistochemistry

Applied immunohistochemistry & molecular morphology, 2019-09, Vol.27 (8), p.589-598

2019

Volltextzugriff (PDF)

Molecular characterization and survival analysis of a cohort of glioblastoma, IDH-wildtype

Pathology, research and practice, 2024-05, Vol.257, p.155272, Article 155272

2024

Volltextzugriff (PDF)

Exome sequencing identifies frequent genomic loss of TET1 in IDH-wild-type glioblastoma

Neoplasia (New York, N.Y.), 2020-12, Vol.22 (12), p.800-808

2020

Volltextzugriff (PDF)

Ensemble learning prediction framework for EGFR amplification status of glioma based on terahertz spectral features

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2024-08, Vol.316, p.124351, Article 124351

2024

Volltextzugriff (PDF)

Analysis of the EGFR Amplification and CDKN2A Deletion Regulated Transcriptomic Signatures Reveals the Prognostic Significance of SPATS2L in Patients With Glioma

Frontiers in oncology, 2021-04, Vol.11, p.551160-551160

2021

Volltextzugriff (PDF)

Beyond sequence variation: assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling

Human pathology, 2019-04, Vol.86, p.170-181

2019

Volltextzugriff (PDF)

Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study

Journal of thoracic oncology, 2016-06, Vol.11 (6), p.910-917

2016

Volltextzugriff (PDF)

Gefitinib Combined with Cetuximab for the Treatment of Lung Adenocarcinoma Harboring the EGFR–Intergenic Region (SEC61G) Fusion and EGFR Amplification

The oncologist (Dayton, Ohio), 2021-11, Vol.26 (11), p.e1898-e1902

2021

Volltextzugriff (PDF)

Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study

BMC gastroenterology, 2021-10, Vol.21 (1), p.1-398, Article 398

2021

Volltextzugriff (PDF)

Genomic Prognosticators and Extent of Resection in Molecularly Subtyped World Health Organization Grade II and III Gliomas–A Single-Institution, Nine-Year Data

World neurosurgery, 2021-07, Vol.151, p.e217-e233

2021

Volltextzugriff (PDF)

IDH mutations in older patients with diffuse astrocytic gliomas

Annals of diagnostic pathology, 2020-12, Vol.49, p.151653-151653, Article 151653

2020

Volltextzugriff (PDF)

Case Report: EGFR-Positive Early-Stage Lung Adenocarcinoma Transforming to Squamous Cell Carcinoma After TKI Treatment

Frontiers in oncology, 2021-06, Vol.11, p.696881

2021

Volltextzugriff (PDF)

Molecular Characterization of IDH Wild-type Diffuse Astrocytomas: The Potential of cIMPACT-NOW Guidelines

Applied immunohistochemistry & molecular morphology, 2022-07, Vol.30 (6), p.410-417

2022

Volltextzugriff (PDF)

EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis

Acta neuropathologica, 2013-05, Vol.125 (5), p.683-698

2013

Volltextzugriff (PDF)

1 – 25 von 691

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(639)
Mit Volltextzugriff
(643)

Publikationsform

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(640)
Life Sciences & Biomedicine
(624)
Humans
(478)
Gene Amplification
(474)
Egfr
(397)
Oncology
(372)
Mutation
(317)
Female
(261)
Tumors
(244)
Kinases
(222)
Middle Aged
(218)
Male
(210)
Receptor, Epidermal Growth Factor - Genetics
(207)
Aged
(191)
Epidermal Growth Factor
(191)
Lung Cancer
(171)
Adult
(160)
Pathology
(154)
Lung Neoplasms - Genetics
(153)
Epidermal Growth Factor Receptors
(143)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma

Case report: EGFR fusion mutation combined with EGFR amplification responds to EGFR-TKI therapy

Detecting EGFR gene amplification using a fluorescence in situ hybridization platform based on digital microfluidics

EGFR/CEP7 high polysomy is separate and distinct from EGFR amplification in glioblastoma as determined by fluorescence in situ hybridization

TP53 Mutation and Extraneural Metastasis of Glioblastoma: Insights From an Institutional Experience and Comprehensive Literature Review

IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroups

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial

Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis

Immunohistochemical and molecular genetic study on epithelioid glioblastoma: Series of seven cases with review of literature

The antitumor activity of osimertinib plus palbociclib in non-small cell lung cancer patient-derived xenograft (PDX)/2D/3D culture models harboring EGFR amplification and CDKN2A/2B homozygous deletions

Heterogeneity of resistant mechanisms in an EGFR-TKI relapsed patient with EGFR amplification and response to nimotuzumab: A case report

Genetic Alterations of Epidermal Growth Factor Receptor in Glioblastoma: The Usefulness of Immunohistochemistry

Molecular characterization and survival analysis of a cohort of glioblastoma, IDH-wildtype

Exome sequencing identifies frequent genomic loss of TET1 in IDH-wild-type glioblastoma

Ensemble learning prediction framework for EGFR amplification status of glioma based on terahertz spectral features

Analysis of the EGFR Amplification and CDKN2A Deletion Regulated Transcriptomic Signatures Reveals the Prognostic Significance of SPATS2L in Patients With Glioma

Beyond sequence variation: assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling

Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study

Gefitinib Combined with Cetuximab for the Treatment of Lung Adenocarcinoma Harboring the EGFR–Intergenic Region (SEC61G) Fusion and EGFR Amplification

Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study

Genomic Prognosticators and Extent of Resection in Molecularly Subtyped World Health Organization Grade II and III Gliomas–A Single-Institution, Nine-Year Data

IDH mutations in older patients with diffuse astrocytic gliomas

Case Report: EGFR-Positive Early-Stage Lung Adenocarcinoma Transforming to Squamous Cell Carcinoma After TKI Treatment

Molecular Characterization of IDH Wild-type Diffuse Astrocytomas: The Potential of cIMPACT-NOW Guidelines

EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis

Suchergebnisse filtern